Literature DB >> 18304050

Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial.

Darren Braude1, Cameron Crandall.   

Abstract

OBJECTIVES: The authors sought to compare ondansetron and promethazine among emergency department (ED) patients with undifferentiated nausea. The hypothesis was that ondansetron was not inferior to promethazine and that rates of adverse effects were similar.
METHODS: This was a randomized double-blind noninferiority clinical trial conducted in an urban academic ED. A convenience sample of nonpregnant adults with at least 40 mm of self-reported nausea measured on a 100-mm visual analog scale (VAS) were enrolled. Patients who had already received more than 1 L of intravenous fluid or an antiemetic agent were excluded. Subjects were block-randomized in groups of 10 to either 4 mg of ondansetron or 25 mg of promethazine delivered intravenously. The primary outcome was change in nausea over 30 minutes. The authors used a 15-mm margin of noninferiority. Secondary endpoints included changes in anxiety, sedation, and other adverse effects. Analyses included t-tests, tests for proportions, and 95% confidence intervals (CIs).
RESULTS: A total of 120 subjects completed the study, 60 in each arm. Baseline nausea, anxiety, and sedation scores were similar. Ondansetron and promethazine reduced nausea similarly (ondansetron -34 mm, promethazine -36 mm; difference -2 mm; 95% CI = -13 to 8 mm). The reduction in anxiety was similar (ondansetron -13 mm, promethazine -14 mm; difference -1 mm; 95% CI = -10 to 10 mm). Promethazine was associated with significantly more sedation than ondansetron (ondansetron 5 mm, promethazine 19 mm; difference 14 mm; 95% CI = 5 to 24 mm). There were no cases of akathisia in the ondansetron group and 2 cases in the promethazine group.
CONCLUSIONS: Promethazine and ondansetron have similar efficacy in reducing nausea among ED patients. Change in anxiety was similar, but promethazine was associated with greater sedation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18304050     DOI: 10.1111/j.1553-2712.2008.00060.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  7 in total

Review 1.  Treatment options for hyperemesis gravidarum.

Authors:  Amy Abramowitz; Emily S Miller; Katherine L Wisner
Journal:  Arch Womens Ment Health       Date:  2017-01-09       Impact factor: 3.633

Review 2.  Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.

Authors:  Jeremy S Furyk; Robert A Meek; Diana Egerton-Warburton
Journal:  Cochrane Database Syst Rev       Date:  2015-09-28

3.  Randomized Controlled Trial of Ondansetron vs. Prochlorperazine in Adults in the Emergency Department.

Authors:  John Patka; Daniel T Wu; Prasad Abraham; Richard M Sobel
Journal:  West J Emerg Med       Date:  2011-02

Review 4.  Vomiting, diarrhea, constipation, and gastroenteritis.

Authors:  Leila Getto; Eli Zeserson; Michael Breyer
Journal:  Emerg Med Clin North Am       Date:  2011-05       Impact factor: 2.264

Review 5.  Emerging Progress in Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum: Challenges and Opportunities.

Authors:  Chuan Liu; Guo Zhao; Danni Qiao; Lintao Wang; Yeling He; Mingge Zhao; Yuanyuan Fan; Enshe Jiang
Journal:  Front Med (Lausanne)       Date:  2022-01-10

6.  Comparison of Low-Dose Promethazine and Dexamethasone against Ondansetron Monotherapy Given as Antiemetic Prophylaxis during Myomectomy Under Spinal Anesthesia: A Randomized Clinical Trial.

Authors:  Emmanuel Onokpite; Abiodun Oyinpreye Jasper; Philomina Nosa Edomwonyi
Journal:  Anesthesiol Res Pract       Date:  2022-08-25

7.  A Review of the Ingredients Contained in Over the Counter (OTC) Cough Syrup Formulations in Kenya. Are They Harmful to Infants?

Authors:  Gabriel Kigen; Naftali Busakhala; Francis Ogaro; Emily Chesire; Nathan Saat; Robert Too; Winstone Nyandiko
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.